valproic acid has been researched along with Body Weight, Fetal in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population." | 3.73 | Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma. ( Holladay, SD; Hrubec, TC; Salafia, CM; Yan, M; Ye, K, 2006) |
| " The supplier group was much more sensitive to these toxic effects." | 1.34 | Valproate-induced developmental neurotoxicity is affected by maternal conditions including shipping stress and environmental change during early pregnancy. ( Hori, Y; Kuwagata, M; Ogawa, T; Shioda, S, 2007) |
| "Valproic acid (VPA) is an anticonvulsant drug that is widely used therapeutically for a variety of neurological conditions." | 1.33 | Myo-inositol enhances teratogenicity of valproic acid in the mouse. ( Finnell, RH; Giavini, E; Massa, V; Wlodarczyk, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Massa, V | 1 |
| Wlodarczyk, B | 1 |
| Giavini, E | 1 |
| Finnell, RH | 1 |
| Hrubec, TC | 1 |
| Yan, M | 1 |
| Ye, K | 1 |
| Salafia, CM | 1 |
| Holladay, SD | 1 |
| Ogawa, T | 1 |
| Kuwagata, M | 1 |
| Hori, Y | 1 |
| Shioda, S | 1 |
| Faiella, A | 1 |
| Wernig, M | 1 |
| Consalez, GG | 1 |
| Hostick, U | 1 |
| Hofmann, C | 1 |
| Hustert, E | 1 |
| Boncinelli, E | 1 |
| Balling, R | 1 |
| Nadeau, JH | 1 |
| Al Deeb, S | 1 |
| Al Moutaery, K | 1 |
| Arshaduddin, M | 1 |
| Tariq, M | 1 |
5 other studies available for valproic acid and Body Weight, Fetal
| Article | Year |
|---|---|
Myo-inositol enhances teratogenicity of valproic acid in the mouse.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anticonvulsants; Drug Synergism; Embryo | 2006 |
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Animals; Anticonvulsants; Dose-Response Relatio | 2006 |
Valproate-induced developmental neurotoxicity is affected by maternal conditions including shipping stress and environmental change during early pregnancy.
Topics: Animal Husbandry; Animals; Anticonvulsants; Antimanic Agents; Brain; Female; Fetal Weight; Fetus; Ma | 2007 |
A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Anticonvulsants; Carcinoma, Embryonal | 2000 |
Vitamin E decreases valproic acid induced neural tube defects in mice.
Topics: Administration, Oral; Animals; Crown-Rump Length; Dose-Response Relationship, Drug; Female; Fetal We | 2000 |